GlaxoSmithKline plc 11.4% Potential Upside Indicated by Liberum Capital

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

GlaxoSmithKline plc with EPIC/TICKER (LON:GSK) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ this morning by analysts at Liberum Capital. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set their target price at 1840 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 11.4% from the opening price of 1651.8 GBX. Over the last 30 and 90 trading days the company share price has decreased 186.2 points and decreased 66.2 points respectively. The 1 year high stock price is 1857 GBX while the 52 week low for the stock is 1485.2 GBX.

GlaxoSmithKline plc has a 50 day moving average of 1,792.53 GBX and the 200 Day Moving Average price is recorded at 1,702.93. There are currently 5,016,413,222 shares in issue with the average daily volume traded being 9,506,582. Market capitalisation for LON:GSK is £83,192,198,098 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement.
    GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development.
    GSK announces FDA review of Nucala for COPD treatment following successful MATINEE study data, aiming to be the first approved monthly biologic.
    GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage.

      Search

      Search